Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Income from Continuing Operations fell 11091.16% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 16005.72%. This contributed to the annual value of $673.7 million for FY2024, which is 29135.13% up from last year.
  • Agios Pharmaceuticals' Income from Continuing Operations amounted to -$103.4 million in Q3 2025, which was down 11091.16% from -$112.5 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Income from Continuing Operations ranged from a high of $947.9 million in Q3 2024 and a low of -$112.5 million during Q2 2025
  • Moreover, its 5-year median value for Income from Continuing Operations was -$91.3 million (2023), whereas its average is -$38.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 113796.92% in 2024, then plummeted by 11091.16% in 2025.
  • Agios Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$98.6 million in 2021, then rose by 5.98% to -$92.7 million in 2022, then dropped by 3.51% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then decreased by 7.16% to -$103.4 million in 2025.
  • Its Income from Continuing Operations stands at -$103.4 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$90.5 million for Q1 2025.